Navigate a path to response in 3L DLBCL— see our data
Confronting cancer with the full potential of our science.
ADC Therapeutics is a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs). ADC Therapeutics is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
Brands: ZYNLONTA® (loncastuximab tesirine-lpyl)